Atossa Therapeutics (MEX:ATOS) Cash Receipts from Operating Activities

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ATOS Atossa Therapeutics Inc MEX:ATOS
28 GF Score
Price MXN44.70
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics Cash Receipts from Operating Activities?

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.

MEX:ATOS
28GF Score
Atossa Therapeutics Inc MEX:ATOS
Cash Receipts from Operating Activities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics Business Description

Other Exchanges ATOS:USAYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company based in the United States that develops proprietary therapeutics for oncology, with a primary focus on breast cancer and related conditions. Its lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader being evaluated in clinical trials for the treatment and prevention of breast cancer, including in neoadjuvant and prevention settings, as well as for other indications such as mammographic breast density. The company also has pursued inhaled drug candidates for respiratory and infectious disease indications. As a clinical-stage company, Atossa does not yet generate product revenue; it funds operations through equity financings and capital markets activity. Its activities are centered on research, clinical development, and regulatory interactions in the United States, with no approved products currently marketed.
28GF Score

Get the complete analysis for MEX:ATOS

Cash Receipts from Operating Activities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN44.70
Price